Факторы , влияющие на трансформацию анапластической глиомы в глиобластому

1. Glioblastoma and other malignant gliomas: a clinical review. Antonio Omuro 1, Lisa M DeAngelis. JAMA . 2013 Nov 6;310(17):1842–50.

2. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Radhakrishnan K, Mokri B, Parisi JE, et al. Ann Neurol. 1995;37(1):67–73.

3. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. Smoll NR, Drummond KJ. J Clin Neurosci. 2012;19(11):1541–1544.

4. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Surawicz TS, McCarthy BJ, Kupelian V , et al. Neuro Oncol. 1999;1(1):14–25.

5. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Smoll NR, Gautschi OP, Radovanovic I, et al. Cancer. 2013;119(11):2029–2037.

6. WHO 2016 Classification of gliomas. P. Wesseling D. Capper. Neuropathology and applied neurobiology, volume 44, page 139–150.

7. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Allen L Ho, Matthew J Koch, Shota Tanaka, April F Eichler, Tracy T Batchelor, Jantima Tanboon, David N Louis, Daniel P Cahill, Andrew S Chi, William T Curry Jr, J Clin Neurosci 2016 Sep;31:99–105.

8. Circulating biomarkers in patients with glioblastoma. Juliana Müller Bark, Arutha Kulasinghe, Benjamin Chua, Bryan W. Day & Chamindie Punyadeera. British Journal of Cancer volume 122, pages 295–305(2020).

9. L iquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges. Ander Saenz-Antoñanzas, Jaione Auzmendi-Iriarte, Estefania Carrasco-Garcia, Leire Moreno-Cugnon, Irune Ruiz, Jorge Villanua, Larraitz Egaña, David Otaegui, Nicolás Samprón, and Ander Matheu,– 2019 Jul; 11(7): 950.

10. G enetic pathways to primary and secondary glioblastoma / H. O hgaki, А. P. Kleihues Am. J. Pathol.– 2007. – Vol. 170, № 5. – Р. 1445–1453/.

11. Isolation of a new cell population in the glioblastoma microenvironment /A. Clavreul, A. Etcheverry, A. Chassevent et al. // J. Neurooncol.– 2012. – Vol. 106, № 3. – Р. 493–504.

12. A dult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Reuss DE, Kratz A, Sahm F, et al. Acta Neuropathol. 2015. doi: 10.1007/s00401‑015‑1454‑8.

13. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. A m J Pathol. 2009; 174(4): 1149–53.

14. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Turcan S, Rohle D, Goenla A, et al. Nature. 2012; 483(7390): 479–83.

15. G lioblastoma: Patterns of Recurrence and Efficacy of Salvage Treatments. Jiwon Oh, Arjun Sahgal, Paul Sanghera, May N. Tsao, Phil Davey, Kelvin Lam, Sean Symons, Richard Aviv, James R. Perry. Can J Neurol Sci. 2011 Jul;38(4):621–5

16. G enetic pathways to primary and secondary glioblastoma. Ohgaki H, Kleihues Am J Path. 2007;170:1445–53.

17. The prognositic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Dropcho EJ, Soong SJ. Neurology. 1996;47:684–90.

18. Prognostic factors for survival in adult patients with cerebral lowgrade glioma. Pignatti F, van den Bent M, Curran D, et al. J Clin Oncol. 2002;20:2076–2084.

19. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. KA Jaeckle, PA Decker, KV Ballman, PJ Flynn, C G iannini, BW Scheithauer, RB Jenkins, and JC Buckner J Neurooncol. 2011 Aug; 104(1): 253–259.